课题基金 / 基金详情

A non-pharmacological multi-modal therapy to improve sleep and cognition and reduce mild cognitive impairment risk

A non-pharmacological multi-modal therapy to improve sleep and cognition and reduce mild cognitive impairment risk
一种非药物多模式疗法,可改善睡眠和认知并降低轻度认知障碍风险
批准号:
10010093
负责人:
Daniel Gartenberg
金额:
$124.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-05-01 至 2022-05-31
关键词:
AccidentsAcoustic StimulationAcousticsAddressAdultAffectAftercareAgeAlgorithmsAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAmyloidApple watchArizonaArousalArtificial IntelligenceAttentionBig DataBiological MarkersBusinessesCardiovascular DiseasesCellular PhoneChronicCircadian RhythmsClientClinicalClinical TreatmentCognitionCognitive TherapyCombined Modality TherapyCommunitiesComorbid InsomniaComputer softwareConsumptionCustomData DisplayData SetDetectionDevicesDiabetes MellitusDiseaseDrowsinessElderlyEnvironmentFeedbackFutureGoalsGoldGrantHealthHealth Services AccessibilityHealthcareHealthcare SystemsHippocampus (Brain)HypertensionIllness DaysImpaired cognitionIndependent LivingIndividualInternet of ThingsInterventionLaboratory StudyLegal patentLettersLightLinkLongitudinal StudiesMaintenanceMalignant NeoplasmsMasksMeasuresMedicalMedicineMemoryMemory impairmentMeta-AnalysisModelingMood DisordersMusNeocortexNerve DegenerationNoiseOlder PopulationOutcomePathologyPatientsPerformancePharmaceutical PreparationsPharmacological TreatmentPharmacologyPhasePhysiologicalPittsburgh Compound-BPlayPopulationPositron-Emission TomographyPrimary InsomniaProcessProductivityPropertyPublic HealthRandomized Clinical TrialsRelaxationResearchRiskRisk FactorsRoleRunningSalesScanningScienceServicesSignal TransductionSleepSleep DeprivationSleep StagesSleep disturbancesSleeplessnessSlow-Wave SleepSolidSonicationStrokeSymptomsSystemTechnologyTelemedicineTestingThalamic structureTimeTrainingUniversitiesValidationWorkabeta depositionactigraphyactive methodagedbasebehavior changebeta amyloid pathologybiomarker panelcognitive functioncognitive performancecognitive taskcognitive testingcostdiariesevidence baseexecutive functionfitbitfunctional disabilityhuman old age (65+)hypnoticimaging studyimprovedimprovement on sleepintervention effectmiddle agemild cognitive impairmentmultimodalityneuroimagingnew technologynon rapid eye movementnovelpersonalized interventionpost interventionprimary outcomerandomized placebo controlled trialregenerativesecondary outcomeside effectsleep healthsleep qualitysleep regulationsoftware developmentsoundstandard carestatisticstau Proteins

项目摘要

项目成果

Daniel Gartenberg的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Summary Our long-term goal is to improve healthcare with non-pharmacological interventions that use the science of behavior change and new Internet of Things (IoT) devices to augment clinical treatment. When you go to the doctor of the future, instead of prescribing a drug, in many cases the doctor may prescribe a software intervention guiding the patient through a process of facilitated behavior change and environmental optimization. This software approach to healthcare addresses the high-priority of providing services to individuals with limited/no access to care and for addressing the public health issues of insomnia and conversion to Mild Cognitive Impairments (MCI) and Alzheimer's Disease (AD). These diseases are thought to cost the US Healthcare system more than $400 billion/year, with another $400 billion/year cost to U.S. businesses in lost productivity, sick days, and accidents. In our Phase I, we were the first research group to show that non-phase locked auditory stimulation can improve next day performance on attention measures without adversely impacting sleep organization, quality, or total sleep time. Our acoustic intervention increased the percentage and intensity of slow-wave sleep (SWS), the stage of sleep with many regenerative properties and which typically decreases with age. We have additional preliminary evidence that this sound-based intervention, played at the right time and volume during sleep, can enhance next day memory performance. Due to the accumulating support demonstrating the role that sleep quality and SWS play in conversion to MCI and AD from imaging studies, longitudinal studies, and cognitive assessments, our intervention may address both the public health issue of poor sleep quality and AD. In our Phase II, we propose to further address insomnia and AD risk by integrating our deep sleep enhancement intervention and sound masking intervetinos with additional IoT devices, such as the FitBit, Apple Watch, and Oura Ring for more accurately measuring sleep and delivering sleep improvement enhancements, such as smart light bulbs to entrain and strengthen circadian rhythms, and Amazon's Alexa to deliver relaxation interventions and reminders to address compliance. The developed software will include a sleep diary with all relevant sleep statistics viewable by a trained therapist in the gold standard treatment for insomnia, cognitive behavioral therapy for insomnia (CBTi). Displaying this data to the clinician can be used to deliver more personalized interventions and increase compliance with the treatment. We propose to conduct a randomized clinical trial on 65+ aged healthy individuals in an independent living facility that have symptoms for insomnia and compare our enhanced type of CBTi integrated with new IoT technology to typical CBTi and a passive control of sleep hygiene therapy. We hypothesize that our intervention is just as effective as the gold standard treatment for insomnia of CBTi as measured by sleep efficiency on a sleep diary (primary outcome). The system may also have the additional benefit of improving next day cognitive performance (secondary outcome), a meaningful indicator of cognitive decline and AD risk. Exploratory analyses further test the effects of the intervention on a neurodegeneration biomarker panel and additional cognitive performance measures.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Business and regulatory development for Integrating sleep enhancement technology into clinical practice
  • 批准号:
    10428404
  • 项目类别:
  • 资助金额:
    $5.0万
  • 财政年份:
    2017
  • 负责人:
    Daniel Gartenberg
  • 依托单位:
海外基金